AU2014314222B2 - Stable polypeptides binding to human complement C5 - Google Patents

Stable polypeptides binding to human complement C5 Download PDF

Info

Publication number
AU2014314222B2
AU2014314222B2 AU2014314222A AU2014314222A AU2014314222B2 AU 2014314222 B2 AU2014314222 B2 AU 2014314222B2 AU 2014314222 A AU2014314222 A AU 2014314222A AU 2014314222 A AU2014314222 A AU 2014314222A AU 2014314222 B2 AU2014314222 B2 AU 2014314222B2
Authority
AU
Australia
Prior art keywords
asp
leu
glu
lie
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2014314222A
Other languages
English (en)
Other versions
AU2014314222A1 (en
Inventor
Joakim Nilsson
Erik Nordling
Patrik Stromberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Swedish Orphan Biovitrum AB
Original Assignee
Swedish Orphan Biovitrum AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Swedish Orphan Biovitrum AB filed Critical Swedish Orphan Biovitrum AB
Publication of AU2014314222A1 publication Critical patent/AU2014314222A1/en
Application granted granted Critical
Publication of AU2014314222B2 publication Critical patent/AU2014314222B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
AU2014314222A 2013-08-28 2014-08-28 Stable polypeptides binding to human complement C5 Active AU2014314222B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE1350986-4 2013-08-28
SE1350986 2013-08-28
PCT/EP2014/068282 WO2015028558A1 (en) 2013-08-28 2014-08-28 Stable polypeptides binding to human complement c5

Publications (2)

Publication Number Publication Date
AU2014314222A1 AU2014314222A1 (en) 2016-04-21
AU2014314222B2 true AU2014314222B2 (en) 2018-05-24

Family

ID=51539238

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014314222A Active AU2014314222B2 (en) 2013-08-28 2014-08-28 Stable polypeptides binding to human complement C5

Country Status (29)

Country Link
US (1) US9994626B2 (https=)
EP (2) EP3038633B1 (https=)
JP (2) JP6767865B2 (https=)
KR (1) KR102446636B1 (https=)
CN (1) CN105658228B (https=)
AU (1) AU2014314222B2 (https=)
BR (1) BR112016003142A2 (https=)
CA (1) CA2926976C (https=)
CY (1) CY1123732T1 (https=)
DK (1) DK3038633T3 (https=)
ES (1) ES2842105T3 (https=)
HR (1) HRP20210013T1 (https=)
HU (1) HUE052613T2 (https=)
IL (1) IL244218A (https=)
LT (1) LT3038633T (https=)
MX (1) MX382140B (https=)
MY (1) MY173804A (https=)
NZ (1) NZ718153A (https=)
PH (1) PH12016500371B1 (https=)
PL (1) PL3038633T3 (https=)
PT (1) PT3038633T (https=)
RS (1) RS61347B1 (https=)
RU (2) RU2020128977A (https=)
SA (1) SA516370622B1 (https=)
SG (1) SG11201602679VA (https=)
SI (1) SI3038633T1 (https=)
SM (1) SMT202100006T1 (https=)
UA (1) UA117933C2 (https=)
WO (1) WO2015028558A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013126006A1 (en) * 2012-02-20 2013-08-29 Swedish Orphan Biovitrum Ab (Publ) Polypeptides binding to human complement c5
MX367423B (es) 2013-08-28 2019-08-21 Affibody Ab Polipeptidos de union a c5.
CN105658228B (zh) * 2013-08-28 2020-02-07 瑞典孤儿比奥维特鲁姆有限公司 结合人类补体c5的稳定多肽
UY37651A (es) * 2017-03-31 2018-10-31 Swedish Orphan Biovitrum Ab Publ Polipéptido de unión al il-1r-i
BR112019028269A2 (pt) 2017-07-11 2020-07-14 Alexion Pharmaceuticals, Inc. polipeptídeos que se ligam ao componente c5 do complemento ou à albumina sérica e suas proteínas de fusão
JP2024506070A (ja) * 2021-02-15 2024-02-08 アフィボディ アクティエボラーグ 新規ｈｅｒ２結合ポリペプチド
CA3237246A1 (en) * 2021-11-01 2023-05-04 Ipc Research, Llc Administration of c5-binding proteins
WO2024227886A1 (en) 2023-05-02 2024-11-07 Mebrahtu Aman Bispecific binding molecule

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002059148A2 (en) * 2001-01-26 2002-08-01 Intercell Ag A method for identification, isolation and production of antigens to a specific pathogen

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
AU2001296594A1 (en) 2000-10-10 2002-04-22 Tanox, Inc. Inhibition of complement c5 activation for the treatment and prevention of delayed xenograft or acute vascular rejection
BRPI0211953B8 (pt) * 2001-08-17 2021-05-25 Genentech Inc anticorpo monoclonal ou fragmento de ligação a antígeno que se liga a c5 e c5a sem a prevenção da formação de c5b, linhagem celular, composição farmacêutica, bem como método in vitro para inibir a atividade de c5a e método de diagnóstico in vitro
ITMI20021527A1 (it) 2002-07-11 2004-01-12 Consiglio Nazionale Ricerche Anticorpi anti componente c5 del complemento e loro uso
WO2005023866A2 (en) 2003-09-10 2005-03-17 Baxter International Inc. Peptides that inhibit complement activation
SE0400274D0 (sv) * 2004-02-09 2004-02-09 Affibody Ab New polypeptide
GB0518443D0 (en) * 2005-09-09 2005-10-19 Evolutec Ltd Method of treating myasthenia gravis
KR101584468B1 (ko) * 2006-03-08 2016-01-13 아케믹스 엘엘씨 안질환의 치료에 유용한 보체 결합 앱타머 및 항-ｃ5 제제
PL3167888T3 (pl) 2006-03-15 2024-08-26 Alexion Pharmaceuticals, Inc. Leczenie pacjentów z napadową nocną hemoglobinurią za pomocą inhibitora dopełniacza
CA2694139C (en) 2007-07-31 2018-06-05 Affibody Ab Albumin binding polypeptide compositions
DK2231860T3 (da) * 2007-12-19 2011-12-05 Affibody Ab Polypeptid afledt protein A og i stand til at binde PDGF
US9187535B2 (en) 2007-12-19 2015-11-17 Affibody Ab Polypeptide derived from protein A and able to bind PDGF
EP2072525A1 (en) 2007-12-21 2009-06-24 Affibody AB New polypeptides having affinity for HER2
PY09026846A (es) 2008-08-05 2015-09-01 Novartis Ag Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5
EP2327725A1 (en) 2009-11-26 2011-06-01 InflaRx GmbH Anti-C5a binding moieties with high blocking activity
MX2013000314A (es) 2010-07-09 2013-01-29 Affibody Ab Polipeptidos.
WO2013126006A1 (en) 2012-02-20 2013-08-29 Swedish Orphan Biovitrum Ab (Publ) Polypeptides binding to human complement c5
JP5980104B2 (ja) 2012-11-22 2016-08-31 三菱電機株式会社 液晶表示装置の製造方法および液晶表示装置の製造システム
EP2935335B1 (en) 2012-12-19 2020-10-28 Affibody AB New polypeptides
MX367423B (es) 2013-08-28 2019-08-21 Affibody Ab Polipeptidos de union a c5.
CN105658228B (zh) * 2013-08-28 2020-02-07 瑞典孤儿比奥维特鲁姆有限公司 结合人类补体c5的稳定多肽

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002059148A2 (en) * 2001-01-26 2002-08-01 Intercell Ag A method for identification, isolation and production of antigens to a specific pathogen

Also Published As

Publication number Publication date
HRP20210013T1 (hr) 2021-04-02
WO2015028558A1 (en) 2015-03-05
IL244218A (en) 2017-11-30
EP3811961A1 (en) 2021-04-28
PL3038633T3 (pl) 2021-07-19
RS61347B1 (sr) 2021-02-26
UA117933C2 (uk) 2018-10-25
KR20160048121A (ko) 2016-05-03
IL244218A0 (en) 2016-04-21
US9994626B2 (en) 2018-06-12
PH12016500371A1 (en) 2016-05-02
MY173804A (en) 2020-02-24
NZ718153A (en) 2022-05-27
PH12016500371B1 (en) 2016-05-02
KR102446636B1 (ko) 2022-09-23
MX2016002397A (es) 2016-09-08
JP2016529270A (ja) 2016-09-23
SG11201602679VA (en) 2016-05-30
CN105658228A (zh) 2016-06-08
EP3811961B1 (en) 2025-08-20
AU2014314222A1 (en) 2016-04-21
RU2733897C2 (ru) 2020-10-09
CA2926976C (en) 2023-11-28
CA2926976A1 (en) 2015-03-05
HK1225656A1 (en) 2017-09-15
SI3038633T1 (sl) 2021-05-31
BR112016003142A2 (pt) 2017-10-17
US20160311870A1 (en) 2016-10-27
SA516370622B1 (ar) 2018-12-23
EP3038633A1 (en) 2016-07-06
HUE052613T2 (hu) 2021-05-28
RU2020128977A (ru) 2021-11-30
DK3038633T3 (da) 2021-01-11
RU2016111115A (ru) 2017-10-03
BR122023020080A2 (pt) 2023-12-26
CN105658228B (zh) 2020-02-07
JP6767865B2 (ja) 2020-10-14
CY1123732T1 (el) 2021-10-29
MX382140B (es) 2025-03-13
EP3038633B1 (en) 2020-10-14
LT3038633T (lt) 2021-03-25
RU2016111115A3 (https=) 2018-04-25
PT3038633T (pt) 2021-01-14
JP2020172505A (ja) 2020-10-22
ES2842105T3 (es) 2021-07-12
SMT202100006T1 (it) 2021-03-15

Similar Documents

Publication Publication Date Title
AU2014314222B2 (en) Stable polypeptides binding to human complement C5
JP6590695B2 (ja) アルブミン結合ポリペプチド
JPWO2018230257A1 (ja) ＩｇＧ結合ペプチド、及び該ペプチドによる抗体の特異的修飾
EP2486058A1 (en) Polypeptides for binding to the "receptor for advanced glycation endproducts" as well as compositions and methods involving the same
MX2013000314A (es) Polipeptidos.
JP2016521688A (ja) 肝細胞増殖因子に結合する設計アンキリン反復タンパク質
CN113785052B (zh) 新重组二胺氧化酶及其治疗以过量组胺为特征的疾病的用途
Cachia et al. Synthetic peptide vaccine development: measurement of polyclonal antibody affinity and cross‐reactivity using a new peptide capture and release system for surface plasmon resonance spectroscopy
CA3212924A1 (en) Multivalent proteins and screening methods
Hirabayashi et al. Kinetic analysis of the interactions of recombinant human VpreB and Ig V domains
HK40050539A (en) Stable polypeptides binding to human complement c5
HK40050539B (en) Stable polypeptides binding to human complement c5
AU2023357539A1 (en) Ultrastable antibody fragments with a novel disuldide bridge
HK1225656B (en) Stable polypeptides binding to human complement c5
CN116262784A (zh) 增强FcRn亲和力的Fc变体
BR122023020080B1 (pt) Polipeptídeos e compostos de ligação a c5 do complemento humano
EP4545554A1 (en) A recombinant polypeptide comprising a metal-binding motif
JP5645155B2 (ja) 分子量マーカー及び分子量マーカーの作製方法
WO2024235270A1 (zh) 补体抑制剂及其制备方法和用途

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)